vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and NICOLET BANKSHARES INC (NIC). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $104.0M, roughly 1.3× NICOLET BANKSHARES INC). NICOLET BANKSHARES INC runs the higher net margin — 38.8% vs 35.5%, a 3.3% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 12.5%). NICOLET BANKSHARES INC produced more free cash flow last quarter ($149.4M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 12.5%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.
ADMA vs NIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $104.0M |
| Net Profit | $49.4M | $40.3M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 48.3% |
| Net Margin | 35.5% | 38.8% |
| Revenue YoY | 18.4% | 12.5% |
| Net Profit YoY | -55.9% | 16.9% |
| EPS (diluted) | $0.20 | $2.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $104.0M | ||
| Q3 25 | $134.2M | $102.9M | ||
| Q2 25 | $122.0M | $95.7M | ||
| Q1 25 | $114.8M | $89.4M | ||
| Q4 24 | $117.5M | $92.4M | ||
| Q3 24 | $119.8M | $90.7M | ||
| Q2 24 | $107.2M | $85.0M | ||
| Q1 24 | $81.9M | $82.2M |
| Q4 25 | $49.4M | $40.3M | ||
| Q3 25 | $36.4M | $41.7M | ||
| Q2 25 | $34.2M | $36.0M | ||
| Q1 25 | $26.9M | $32.6M | ||
| Q4 24 | $111.9M | $34.5M | ||
| Q3 24 | $35.9M | $32.5M | ||
| Q2 24 | $32.1M | $29.3M | ||
| Q1 24 | $17.8M | $27.8M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 48.3% | ||
| Q3 25 | 38.0% | 50.4% | ||
| Q2 25 | 35.1% | 46.8% | ||
| Q1 25 | 30.4% | 44.9% | ||
| Q4 24 | 32.6% | 46.8% | ||
| Q3 24 | 33.1% | 45.0% | ||
| Q2 24 | 36.6% | 43.3% | ||
| Q1 24 | 26.7% | 41.8% |
| Q4 25 | 35.5% | 38.8% | ||
| Q3 25 | 27.1% | 40.6% | ||
| Q2 25 | 28.1% | 37.6% | ||
| Q1 25 | 23.4% | 36.4% | ||
| Q4 24 | 95.2% | 37.3% | ||
| Q3 24 | 30.0% | 35.8% | ||
| Q2 24 | 29.9% | 34.5% | ||
| Q1 24 | 21.7% | 33.8% |
| Q4 25 | $0.20 | $2.63 | ||
| Q3 25 | $0.15 | $2.73 | ||
| Q2 25 | $0.14 | $2.34 | ||
| Q1 25 | $0.11 | $2.08 | ||
| Q4 24 | $0.45 | $2.21 | ||
| Q3 24 | $0.15 | $2.10 | ||
| Q2 24 | $0.13 | $1.92 | ||
| Q1 24 | $0.08 | $1.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | $134.9M |
| Stockholders' EquityBook value | $477.3M | $1.3B |
| Total Assets | $624.2M | $9.2B |
| Debt / EquityLower = less leverage | 0.15× | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — | ||
| Q1 24 | $45.3M | — |
| Q4 25 | $72.1M | $134.9M | ||
| Q3 25 | $72.4M | $134.6M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | — | $156.6M | ||
| Q4 24 | $72.3M | $161.4M | ||
| Q3 24 | — | $161.2M | ||
| Q2 24 | — | $162.4M | ||
| Q1 24 | — | $162.3M |
| Q4 25 | $477.3M | $1.3B | ||
| Q3 25 | $431.2M | $1.2B | ||
| Q2 25 | $398.3M | $1.2B | ||
| Q1 25 | $373.4M | $1.2B | ||
| Q4 24 | $349.0M | $1.2B | ||
| Q3 24 | $231.9M | $1.1B | ||
| Q2 24 | $188.3M | $1.1B | ||
| Q1 24 | $153.7M | $1.1B |
| Q4 25 | $624.2M | $9.2B | ||
| Q3 25 | $568.7M | $9.0B | ||
| Q2 25 | $558.4M | $8.9B | ||
| Q1 25 | $510.6M | $9.0B | ||
| Q4 24 | $488.7M | $8.8B | ||
| Q3 24 | $390.6M | $8.6B | ||
| Q2 24 | $376.4M | $8.6B | ||
| Q1 24 | $350.9M | $8.4B |
| Q4 25 | 0.15× | 0.11× | ||
| Q3 25 | 0.17× | 0.11× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | 0.21× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $153.5M |
| Free Cash FlowOCF − Capex | $34.6M | $149.4M |
| FCF MarginFCF / Revenue | 24.8% | 143.7% |
| Capex IntensityCapex / Revenue | 0.8% | 3.9% |
| Cash ConversionOCF / Net Profit | 0.72× | 3.81× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $275.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $153.5M | ||
| Q3 25 | $13.3M | $45.9M | ||
| Q2 25 | $21.1M | $38.9M | ||
| Q1 25 | $-19.7M | $41.8M | ||
| Q4 24 | $50.2M | $133.7M | ||
| Q3 24 | $25.0M | $39.6M | ||
| Q2 24 | $45.6M | $37.3M | ||
| Q1 24 | $-2.2M | $23.4M |
| Q4 25 | $34.6M | $149.4M | ||
| Q3 25 | $-1.1M | $45.9M | ||
| Q2 25 | $18.7M | $38.4M | ||
| Q1 25 | $-24.4M | $41.3M | ||
| Q4 24 | $47.5M | $116.8M | ||
| Q3 24 | $24.0M | $34.7M | ||
| Q2 24 | $43.6M | $34.4M | ||
| Q1 24 | $-4.6M | $20.1M |
| Q4 25 | 24.8% | 143.7% | ||
| Q3 25 | -0.8% | 44.6% | ||
| Q2 25 | 15.3% | 40.1% | ||
| Q1 25 | -21.2% | 46.2% | ||
| Q4 24 | 40.4% | 126.4% | ||
| Q3 24 | 20.0% | 38.3% | ||
| Q2 24 | 40.7% | 40.5% | ||
| Q1 24 | -5.6% | 24.4% |
| Q4 25 | 0.8% | 3.9% | ||
| Q3 25 | 10.7% | 0.0% | ||
| Q2 25 | 2.0% | 0.6% | ||
| Q1 25 | 4.1% | 0.5% | ||
| Q4 24 | 2.3% | 18.3% | ||
| Q3 24 | 0.9% | 5.4% | ||
| Q2 24 | 1.9% | 3.5% | ||
| Q1 24 | 2.9% | 4.0% |
| Q4 25 | 0.72× | 3.81× | ||
| Q3 25 | 0.36× | 1.10× | ||
| Q2 25 | 0.62× | 1.08× | ||
| Q1 25 | -0.73× | 1.28× | ||
| Q4 24 | 0.45× | 3.88× | ||
| Q3 24 | 0.70× | 1.22× | ||
| Q2 24 | 1.42× | 1.28× | ||
| Q1 24 | -0.12× | 0.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
NIC
Segment breakdown not available.
